1. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. (4th February 2014) Authors: Rommer, P. S.; Zettl, U. K.; Kieseier, B.; Hartung, H.‐P.; Menge, T.; Frohman, E.; Greenberg, B. M.; Hemmer, B.; Stüve, O. Journal: Clinical and experimental immunology Issue: Volume 175:Number 3(2014:Mar.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice. (1st May 2019) Authors: Yan, B.Y.; Hibler, B.P.; Menge, T.; Dunn, L.; Ho, A.L.; Rossi, A.M. Journal: British journal of dermatology Issue: Volume 180:Number 5(2019) Page Start: 1260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice. (7th March 2019) Authors: Yan, B.Y.; Hibler, B.P.; Menge, T.; Dunn, L.; Ho, A.L.; Rossi, A.M. Journal: British journal of dermatology Issue: Volume 180:Number 5(2019) Page Start: 1260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Spray‐dried plasma and fresh frozen plasma modulate permeability and inflammation in vitro in vascular endothelial cells. (10th January 2013) Authors: Wataha, K.; Menge, T.; Deng, X.; Shah, A.; Bode, A.; Holcomb, J.B.; Potter, D.; Kozar, R.; Spinella, P.C.; Pati, S. Journal: Transfusion Issue: Volume 53(2013)Supplement 1 Page Start: 80S Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗